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Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors
and its value as a serum marker in hepatocellular carcinomas
Abstract
Hepatocellular carcinomas (HCCs) and bile duct carcinomas (BDCs) have a poor prognosis. Therefore,
surveillance strategies including sensitive and specific serum markers for early detection are needed.
Recently, Golgi Phosphoprotein 2 (GOLPH2) has been proposed as a serum marker for HCC, but
GOLPH2 expression data in liver tissues was not available. Using tissue microarrays and
immunohistochemistry, we semiquantitatively analyzed GOLPH2 protein expression in patients with
HCC (n = 170), benign liver tumors (n = 22), BDC (n = 114) and normal liver tissue (n = 105). A newly
designed sandwich enzyme-linked immunoassay (ELISA) was used to analyze GOLPH2 levels in the
sera of patients with HCC (n = 62), hepatitis C virus (HCV) (n = 29), BDC (n = 10), and healthy control
persons (n = 12). By immunohistochemistry 121/170 (71%) of HCC showed strong GOLPH2
expression, which was significantly associated with a higher tumor grade (P = 0.01). A total of 97/114
(85%) BDCs showed a strong GOLPH2 expression which proved to be an independent prognostic factor
for overall survival (P < 0.05). Serum levels of GOLPH2 measured by ELISA were significantly
elevated in patients with HCC with underlying HCV infection (median 18 mg/L, P < 0.05) and patients
with BDC (median = 14.5 mg/L, P < 0.01) in comparison to healthy controls (median 4 mg/L).
Conclusion: GOLPH2 protein is highly expressed in tissues of HCC and BDC. GOLPH2 protein levels
are detectable and quantifiable in sera by ELISA. In patients with hepatitis C, serial ELISA
measurements in the course of the disease appear to be a promising complementary serum marker in the
surveillance of HCC. GOLPH2 should be further evaluated as a serum tumor marker in BDC on a larger
scale.
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Abstract 
Hepatocellular Carcinomas (HCC) and Bile Duct Carcinomas (BDC) have a poor 
prognosis. Therefore, surveillance strategies including sensitive and specific serum 
markers for early detection are needed. Recently, GOLPH2 has been proposed as a 
serum marker for HCC, but GOLPH2 expression data in liver tissues was not available. 
Using tissue microarrays and immunohistochemistry we semiquantitatively analysed 
GOLPH2 protein expression in patients with HCC (n=170), benign liver tumors (n=22) 
BDC (n=114) and normal liver tissue (n=105). A newly designed sandwich ELISA was 
used to analyse GOLPH2 levels in the sera of patients with HCC (n=62), HCV (n=29), 
BDC (n=10) and healthy control persons (n=12). 
By immunohistochemistry 121/170 (71%) of HCC showed strong GOLPH2 expression, 
which was significantly associated with a higher tumor grade (p=0.01). 97/114 (85%) 
BDCs showed a strong GOLPH2 expression which proved to be an independent 
prognostic factor for overall-survival (p<0.05).  
Serum levels of GOLPH2 measured by ELISA were significantly elevated in HCC patients 
with underlying HCV infection (median 18mg/L, (p<0.05) and patients with BDC 
(median=14.5mg/L, p<0.01) in comparison to healthy controls (median 4mg/L). 
Conclusions: GOLPH2 protein is highly expressed in tissues of HCC and BDC. GOLPH2 
protein levels are detectable and quantifiable in sera by ELISA. In Hepatitis C patients 
serial ELISA measurements in the course of the disease appear to be a promising 
complementary serum marker in the surveillance of HCC. GOLPH2 should be further 
evaluated as a serum tumor marker in BDC on a larger scale. 
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1. Introduction 
Hepatocellular carcinomas (HCC) and Bile-Duct Carcinomas (BDC) are the most common 
malignant tumors of the liver and they are frequently detected in advanced stages with 
a poor prognosis (1, 2). HCC often arises in the background of chronic liver disease and 
cirrhosis. In these patients surveillance strategies for the detection of early HCC are 
necessary. They include imaging techniques and serum markers such as AFP which has 
its limits (3). Therefore better markers are clearly needed (4). Recently GOLPH2/GP73, a 
Golgi apparatus associated protein, has been shown to have a higher sensitivity than 
AFP in the detection of HCC (5).  Immunohistochemically GOLPH2 has been found in 
normal biliary epithelial cells whereas normal hepatocytes were negative (6). 
Furthermore GOLPH2 expression was significantly increased in liver disease due to viral 
causes (HBV, HCV) compared to nonviral causes (alcohol-induced liver disease, 
autoimmune hepatitis) (6). To our knowledge GOLPH2 protein expression has not yet 
been studied in tissues of liver tumors. 
In this study, we performed a comprehensive GOLPH2 protein expression analysis in 
resection specimen of patients with HCC, liver-cell adenoma (LCA), focal nodular 
hyperplasia (FNH) and BDC using clinically well characterised tissue microarrays and 
correlated our findings with clinical-pathological parameters including patient survival.   
Further, a sandwich ELISA was created allowing serum level measurements and 
detection of anti-GOLPH2 antibody development in the serum. Applying this ELISA, sera 
from healthy individuals were compared to sera from patients with chronic hepatitis 
infections, HCC of various etiologies and BDC. 
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2. Material and Methods 
Patients with hepatocellular tumors 
One-hundred-seventy patients with HCC, 10 with LCA and 12 with FNH who 
underwent surgery between 1992 and 2007 in Zürich (n=110) and Regensburg (n=82) 
were enclosed in this study. In the HCC group the patients’ age ranged from 20 to 85 
years (median 61 years). The underlying liver diseases of the HCC were: HBV-infection 
(27, 15.8%), HCV-infection (37, 21.7%), alcohol abuse (46, 27.1%), hemochromatosis 
(4, 2.4%), Alagille’s syndrome (1, 0.6%) and unknown etiologies (55, 32.4%). Of the 
55 cases with unknown etiology, 30 (54.5%) suffered from concomitant liver cirrhosis. 
Corresponding non-neoplastic liver tissue of 100 patients with HCC, 8 patients with LCA 
and 9 patients with FNH was available. The median follow-up time of all patients was 17 
months (range 1 to 120 months).  Median follow up time of patients without disease 
progression was 17 months (range 1 to 120 months). Thirty-six percent of patients died 
during follow up after a median time of 14 months (range 1 to 79 months).  
 
Patients with bile duct carcinoma 
One-hundred-fourteen patients with bile duct carcinomas (BDC) who underwent surgery 
between 1995 and 2007 in Zürich were enclosed in this study. The BDC group consisted 
of 19 intrahepatic cholangiocarcinomas (ICC), 57 extrahepatic cholangiocarcinomas 
(ECC) and 38 gall bladder carcinomas (GBC). Patient age ranged from 36 to 90 years 
(median 64 years). Survival data was available for 109 patients. The median follow-up 
time of all cases was 9 months (range 1 to 86 months). Median follow up time of 
patients without disease progression was 11 months (range 1 to 58 months). Fifty-seven 
percent of patients died during follow up after a median time of 7.5 months (range 1 to 
86 months).  
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Normal tissue 
In order to evaluate GOLPH2 expression in normal liver and bile ducts five specimens of 
liver resections due to metastasis of colorectal carcinomas without specific liver disease 
were used. Five gall bladder resection specimens with mild chronic cholecystitis including 
normal epithelium were analysed for GOLPH2 expression in normal gall bladder 
epithelium. 
 
Tissue Microarray 
Formalin-fixed paraffin-embedded tissues were used to construct five tissue microarrays 
(TMA) with liver tumor tissues and two TMA with BDC tissues. The TMA was 
constructed as described previously (7). Two tissue cores per tumor with a diameter of 
0.6 mm were punched out of the donor block and transferred to the recipient block.  
 
Immunohistochemistry 
The TMA blocks were freshly cut (3μm) and mounted on superfrost slides (Menzel 
Gläser, Braunschweig, Germany). Immunohistochemistry was conducted with the 
Ventana Benchmark automated staining system (Ventana Medical Systems, Tucson, AZ, 
USA) using Ventana reagents for the entire procedure. A monoclonal mouse antibody 
(clone 5B10, Abnova Corporation, Taipei, Taiwan, catalogue number H00051280-M06, 
dilution 1:1000) was diluted in a Ventana diluent, as recently described (8). The primary 
antibody was detected using the UltraVIEW DAB detection kit using the benchmarks 
CC1m- heat induced epitope retrieval. Slides were counterstained with hematoxylin, 
dehydrated and mounted. Prostatic tissue was used as a positive control.  
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Evaluation of the immunohistochemical stainings 
The staining intensity of GOLPH2 was semiquantitatively evaluated with a four-tired 
system: 0 (negative), 1+ (weak), 2++ (moderate), 3+++ (strong). Weak immunoreactivity 
was defined as minute granules projecting to the Golgi apparatus. Moderate 
immunoreactivity was diagnosed when a coarser and more intense staining was seen, 
whereas chunky, dark lumps were scored as strongly positive.  A tumor was scored as 
positive when at least 10% of the tumor cells were stained. For statistical analysis, 
tumors were grouped into GOLPH2 weakly (0&1) and strongly (2&3) positive. The 
proliferation rate (MiB-1) was defined as percentage of positive nuclei per 100 tumor 
cells as recently described (9). The immunostainings were evaluated by two pathologists 
(MOR, GK) simultaneously on a multiheaded microscope.  
 
Serological Tests 
Serum samples (n =113, 62 HCC, 29 from patients with chronic hepatitis C Infection 
(HCV), 10 BDC and 12 healthy volunteers) were collected from consented patients and 
healthy individuals.  
Sera of patients were submitted to an ELISA for detection of serum GOLPH2 (sGOLPH2). 
The results were compared to serum values of healthy controls. The ELISA was 
performed as a sandwich ELISA as follows: 
 Maxisorb plates (NUNC, Langenselbold, Germany) were coated overnight at 4°C with 
0.5 μg/ml polyclonal goat serum against GOLPH2 (Novus Biologicals; Littleton, CO, 
USA). The following day plates were washed with PBS and blocked using 10% Bovine 
Serum Albumin (BSA) (Sigma Aldrich; St. Louis, MO, USA) and 0.5% Tween 20 (Sigma) 
in PBS for 1 hour at room temperature. Serum samples were diluted 1:10 in PBS and 
applied in triplicate to the plate for 1.5 hours at room temperature. In some cases, due 
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to high concentrations of GOLPH2, further dilutions of sera were necessary (up to 
1:500). Recombinant human GOLPH2 protein was plated in doubled increasing 
concentrations (0.025g/ml, 0.05g/ml, 0.1g/ml, 0.2g/ml, 0.4g/ml, 0.8g/ml, 
1.6g/ml, 3.2g/ml, 6.4g/ml) in triplicate. Plates were washed 5 times with PBS.  The 
polyclonal rabbit serum against GOLPH2 (abcam; Cambridge UK) was employed for 1 
hour at room temperature in a dilution of 1:1000 in PBS. After washing, a horseradish 
linked secondary anti-rabbit antibody (Sigma) diluted 1:10 000 in PBS was added for 45 
minutes and plates were again washed extensively (7x PBS). Wells were replenished with 
100 μl staining solution (TMB-solution) (Pierce, Thermo scientific, Rockford, IL, USA) per 
well and left at RT in the dark for 20 minutes. The colour reaction was stopped by 
adding 50μl 2 N H2SO4 to each well. The absorbance at 450nm was measured using an 
Emax microplate reader (Molecular device cooperation, CA, USA) and analysed with 
Softmax Pro V3.0 software. AFP serum levels were determined by TRACE (Time resolved 
Amplified Cryptate Emission).  
 
Cloning and expression of recombinant human GOLPH2 protein 
For the production of recombinant GOLPH2 protein to be used for reference 
measurements in the ELISA, the cDNA of GOLPH2 (ORF clone GOLM1 Transcript 
Variant1, Origene Technologies, Inc.; Rockville, USA) was amplified by polymerase chain 
reaction (PCR) using the following primer pair:  
5´AAGAATTCGAGATGATGGGCTTGGGAAACG-3´  and  
5´-AAAGGATCCGAGTGTATGATTCCGCTTTTCACG -3´. The PCR product was subcloned 
into the ECORI and BAMHI sites of pEAK8 (Edge BioSystems, Gaithersburg, MD, USA) 
that had been modified to contain the additional BAMHI and a 6 x histidine-tag in its 
multi-cloning site previously. The inserted cDNA was confirmed by complete sequencing. 
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The GOLPH2-HIS fusion product was transiently expressed in HEK-293 cells and detected 
by Western blotting in whole cell lysate and supernatant of these cells. 
 
Generation of stable cell lines for production of recombinant GOLPH2 protein 
HEK-293cells were cultured in DMEM supplemented with10% fetal calf serum, 50U/ml 
Penicillin 50ug/ml Streptomycin and 2mM L-Glutamin (Gibco Invitrogen; Carlsbad, USA).  
The cells were transfected with pEAK8-GOLPH2-HIS using Lipofectamin 2000 
(Invitrogen; Carlsbad, CA,USA) according to the manufacturer´s recommendations.  
At 24 h postinfection, media of cells were supplied with puromycin. Remaining cells 
were subcloned and supernatants of clones expressing GOLPH2 were tested by 
immunoblots. A highly GOLPH2 expressing clone (H-G8 cells) was expanded and 
propagated for continuous production. Human recombinant GOLPH2-HIS protein was 
detectable in whole cell lysate and supernatant of H-G8 cells by ELISA and Western 
blotting (not shown). For purification supernatant of these stable cell line was dialysed 
against phosphate buffer (0.5M NaCl, 20mM Na Phosphate pH 7.3). His-tagged 
GOLPH2 was bound overnight on TALON metal affinity resin (Clontech; Mountain View, 
CA, USA). Washed resin (10 x resin bed volume with phosphate buffer) was eluted with 
increasing concentrations of imidazole (Sigma) from 15 mM  to 250 mM and dialysed 
against PBS. Fractions were tested for GOLPH2 by Immunoblotting and for purity on 
Coomassie  stained 10% SDS-Page gel. Concentration was measured using a Bradford 
assay (BioRad Laboratories AG; Reinach Switzerland).  
 
Statistical analysis 
Statistical analysis was performed using SPSS, version 15.0. Correlations were calculated 
according to Spearman. Fisher´s exact and chi-square tests were applied to assess the 
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statistical significance of the associations between the expression of GOLPH2 and 
various clinico-pathological parameters. Univariate survival analysis was carried out 
according to Kaplan-Meier, differences in survival curves were assessed with the Log 
rank test. Multivariate analyses were calculated according to the Cox regression model. 
P values < 0.05 were considered significant. 
 
The study was approved by the local ethics committee (Kantonale Ethikkommission 
Zurich, StV 26-2005 and EK-1017). 
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3. Results 
GOLPH2 protein expression in normal liver and bile duct tissue 
Normal bile duct and gall bladder epithelium showed a weak GOLPH2 expression. The 
staining pattern was dot-like and localized perinuclear towards the cells apex projecting 
to the Golgi apparatus, while the cytoplasm was negative (Figure 1). A diffuse 
cytoplasmic GOLPH2 immunoreactivity that we have noted recently in a small subset of 
prostate cancer cases, was not seen. Interestingly single periportal hepatocytes were 
weakly positive while the rest of the hepatocytes were completely negative (Figure 1). In 
mesenchymal, stellate and endothelial cells we noted a weak to moderate dot-like 
GOLPH2 positivity similar to the description of Iftikhar et al. (10) and which we have also 
observed in other organs (Figure 1 and Figure 3) (8). In cirrhotic livers of different 
etiologies strong GOLPH2 expression in hepatocytes was found more frequently in 
patients with HCV infection (p<0.01, Table 1). 
 
GOLPH2 protein expression in hepatocellular liver tumors and correlation with clinical-
pathological parameters 
121/170 (71.2%) of the HCC were strongly positive for GOLPH2 compared to 38/100 
(38.0%) of the corresponding non-tumorous tissue (p<0.0001, Table 2). Strong GOLPH2 
expression correlated significantly with a higher tumor grade (p<0.01) while no 
correlation with the other clinical-pathological parameters or survival was found 
(Supplemental Table 1, Supplemental Figure 1). 
In contrast to normal liver tissue peritumoral tissue of LCA and FNH was strongly positive 
for GOLPH2 without a significant difference between tumor and non-tumorous tissue. 
8/10 (80.0%) LCA were strongly GOLPH2 positive compared to 4/8 (50.0%) of the 
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corresponding peritumoral liver tissue while 4/12 (33.3%) of FNH compared to 1/9 
(11.1%) of the peritumoral tissue (Supplemental Figure 2). 
 
GOLPH2 protein expression in BDC and correlation with clinical-pathological parameters 
17/19 (89.5%) of the ICC, 52/57 (91.2%) ECC and 28/38 (73.7%) GBC were strongly 
GOLPH2 positive (Figure 3). Due to the similarities in the GOLPH2 expression all these 
carcinomas were summarized as BDC. Taken together, 97/114 (85.1%) of these 
carcinomas showed a strong GOLPH2 expression. In this cohort GOLPH2 expression 
correlated with a younger patient age (p<0.01) while no correlation with other clinical-
pathological parameters was found (Supplemental Table 2). Patients with BDC and 
GOLPH2 expression had a better overall survival as assessed by univariate analysis 
(p<0.001, Supplemental Figure 1).  Further prognostic factors in our study group 
included patients age at diagnosis (<60 years vs. ≥60 years, p<0.05), higher pT-stage 
(pT1,2 vs. pT3,4, p<0. 05) and R-status (p<0.001). In multivariate analysis including 
GOLPH2 expression, R-status, pT-stage and age, GOLPH2 expression was an 
independent prognostic factor for overall-survival (p<0.05, Table 3).  
 
Analysis of GOLPH2 protein in Sera 
Levels of circulating GOLPH2 protein (sGOLPH2) were studied with a newly generated 
sandwich ELISA in sera of patients and control persons. When testing commercially 
available antibodies we found the combination of goat anti GOLPH2 for capturing the 
antigen and rabbit anti GOLPH2 for detection to be the most robust and reproducible 
design. Using this ELISA we measured sGOLPH2 levels in the range of  
1.5 μg/ml to 60 μg/ml with 5% of sera exceeding the upper range. 
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The sGOLPH levels in this study are in the range of serum levels found for IL-2, IL-6 IL-8, 
TNF- (11), CCSA-2 (colon cancer specific antigen 2) (12), Glypican-3 in HCC patients 
(13) or C-reactive protein (CRP).  
Serum GOLPH2 levels of healthy controls were in the range of 1.5μg/ml to 20 μg/ml 
with a median of 4 μg/ml. Elevations were seen in patients affected by hepatitis C 
(median 9 μg/ml) and HCC of alcohol induced liver disease (AILD) etiology (median 
7μg/ml). A more pronounced rise was found in patients with hepatitis C derived HCC 
(median 18μg/ml), especially if infected with HCV genotype 1b (median 19μg/ml) (Figure 
4). In HCV positive HCC patients GOLPH2 serum levels were significantly higher than in 
sera of healthy controls (p<0.05). A non-significant trend towards higher values was 
seen in sera levels of HCC patients with a HCV-etiology compared to patients with a 
HCV-hepatitis (p=n.s.; Figure 4).  
No correlation was noted between serum AFP and serum GOLPH2 levels (Figure 5). By 
setting the cut-off for sGOLPH2 at 10mg/L (above the 95% confidence interval of 
healthy references) and AFP at 10ng/ml approximately 30% of HCC cases exceeded this 
range for either GOLPH2 or AFP only. Both markers were elevated in 27% of cases and 
only 14% of patients were negative for both markers.  
In the sera of patients with BDC (n=10) sGOLPH2 levels were significantly elevated 
(p<0.001) 
  
HEP-08-1321.R1  14  
4. Discussion 
The data presented in this study provides further evidence that GOLPH2 protein is 
strongly expressed in HCC and BDC tissues and is secreted into the blood. 
The 73kDa Golgi apparatus associated protein GOLPH2 is coded by the gene GOLM1 
located on chromosome 9q21.33 and was originally cloned from a library derived from 
liver tissue of a patient with adult giant-cell hepatitis (14). GOLPH2 functions and the 
mechanisms of regulation in normal and neoplastic tissues are still unclear. Possibly it is 
either involved in posttranslational protein modification, transport of secretory proteins, 
cell signalling regulation or simply maintenance of Golgi apparatus function. GOLPH2 
has several potential glycosylation sites and up to 75% of GOLPH2 secreted from 
hepatocytes is fucosylated (15). Endosomal trafficking of the normally membrane bound 
GOLPH2 leads to secretion into the blood making it a potential serum biomarker for 
HCC (16).  
Surgical resection or liver transplantation are the only therapeutic options with curative 
intent for patients with HCC hence early detection is of utmost importance. Since most 
HCC develop in cirrhotic livers surveillance strategies for these patients have been 
employed including radiological and serological tests. One of the most commonly used 
approaches combines ultrasonography and serum AFP (sAFP) at an interval of 6-12 
months (3). Unfortunately sAFP has a poor sensitivity, ranging from 39% to 65% and a 
specificity ranging from 76% to 97%. Therefore additional or better serum markers are 
needed (17). Recently, GOLPH2 was found to be up-regulated in sera of patients with 
HCC compared to healthy individuals and it was assumed that it might serve as a novel 
serum marker for HCC (5, 18). Unfortunately the authors found the applied immunoblot 
assay unsuitable for routine practice (5). 
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Previous studies have shown a better sensitivity of GOLPH2 than alpha-fetoprotein (5). In 
our study serum levels of sGOLPH2 and sAFP did not correlate, pointing to a diverse 
underlying cause of their elevation in HCC. Up-regulation of GOLPH2 was found in 
HepG2 cells after adenoviral infection suggesting that GOLPH2 is a marker for viral 
infection in liver tissue (6). This is in agreement with our findings of a significantly higher 
GOLPH2 expression in non-neoplastic liver tissue with HCV infection compared to other 
etiologies. In addition, most profound elevation of serum levels of GOLPH2 was 
detected in patients that had developed a HCC on the background of HCV genotype 1b 
infection. The control group with HCV genotype 1b infection without tumor had lower 
values in the ELISA test than the tumor bearing HCV infected patients but that 
difference did not reach significance. HCC of different etiologies like ethanol, other 
hepatitis subgroups including hepatitis C of other genotypes were not as clearly 
distinguishable by this method. However, due to the still limited number of serum 
samples analysed in this study, these results ought to be validated in a larger cohort. 
The need for closer monitoring of chronically hepatitis infected individuals having a high 
risk of developing HCC during the course of the disease (19) has long been stated. In 
these patients sAFP has been a particularly unsatisfactory screening tool for early 
detection of HCC (20). From our preliminary experience we conclude that GOLPH2 is 
not a general HCC serum tumor marker but could rather be a valuable complementary 
tool in the surveillance of patients “at risk”. Further prospective studies are required to 
determine the predictive value of sequential measurement of serum AFP and sGOLPH2 
as a new surrogate marker combination in the development of HCC. 
Although GOLPH2 has been studied in normal liver and sera of patients with chronic 
liver disease and HCC, data about its protein expression in HCC tissue is lacking. In our 
study we found it highly expressed in the majority of the cases studied. Additionally it is 
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expressed frequently in the tissue of LCA and FNH and in the corresponding peritumoral 
liver tissue suggesting that it is not a specific marker for HCC. 
Furthermore we found a high tissue expression of GOLPH2 in BDC. Interestingly, 
patients with high GOLPH2 expression in their tumors had a significantly better overall 
survival even in multivariate analysis, an unexpected finding that clearly warrants further 
confirmatory study. In the absence of established serum markers for BDC the raised 
sGOLPH2 levels in our ten BDC patients is an intriguing initial finding warranting further 
evaluation.  
Increased GOLPH2 serum levels have been previously suggested as a specific finding for 
HCC. We have recently reported high tissue levels of GOLPH2 in adenocarcinomas of 
various organs including prostate, breast, colon (8) and some subtypes of renal cell 
carcinomas (21), which might confound the specificity of GOLPH2 as a serum marker for 
HCC. However, Block et al. did not find elevated sGOLPH2 levels in sera of nine patients 
with colorectal cancer (18) and Varambally et al. could not detect sGOLPH2 in serum of 
prostate cancer patients (22) using immunoblots. Still, more data is needed to clarify, if 
carcinomas other than HCC/BDC actively shed GOLPH2 into the serum. 
While this paper was under revision a study showing similar results for serum GOLPH2 
frequencies in liver diseases was published (23). Despite high concordance of our 
findings with regard to results and conclusions, Gu et al. measured approximately 100-
fold lower absolute sGOLPH2 concentrations. This discrepancy is most likely due to 
methodological differences. The combination of the well characterised commercially 
available antibodies and a fully human recombinant standard protein presented herein 
may detect higher amounts of secondarily modified sGOLPH2 levels not recognized by a 
prokaryotic based detection system. 
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Taken together we found GOLPH2 protein highly expressed in HCC and BDC tumor 
tissues. Serum GOLPH2 measurements have promising potential for diagnostic and 
surveillance strategies of HCC patients.  
 
5. Acknowledgments 
We are grateful to Martina Storz, Silvia Behnke and Norbert Markuly for excellent 
technical assistance. 
  
HEP-08-1321.R1  18  
References 
 
 
1. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin 
Oncol 2005;23:2892-2899. 
2. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005;128:1655-
1667. 
3. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 
2005;42:1208-1236. 
4. Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, Wagner PD. 
The degree of readiness of selected biomarkers for the early detection of hepatocellular 
carcinoma: notes from a recent workshop. Cancer Biomark 2008;4:19-33. 
5. Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ, Comunale 
MA, et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for 
hepatocellular carcinoma. J Hepatol 2005;43:1007-1012. 
6. Kladney RD, Cui X, Bulla GA, Brunt EM, Fimmel CJ. Expression of GP73, a 
resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 
2002;35:1431-1440. 
7. Riener MO, Bawohl M, Clavien PA, Jochum W. Rare PIK3CA hotspot mutations in 
carcinomas of the biliary tract. Genes Chromosomes Cancer 2008. 
8. Kristiansen G, Fritzsche FR, Wassermann K, Jager C, Tolle A, Lein M, Stephan C, 
et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: 
implications for tissue-based diagnostics. Br J Cancer 2008;99:939-948. 
9. Riener MO, Wild PJ, Soll C, Knuth A, Jin B, Jungbluth A, Hellerbrand C, et al. 
Frequent expression of the novel cancer testis antigen MAGE-C2/CT-10 in hepatocellular 
carcinoma. Int J Cancer 2009;124:352-357. 
  
HEP-08-1321.R1  19  
10. Iftikhar R, Kladney RD, Havlioglu N, Schmitt-Graff A, Gusmirovic I, Solomon H, 
Luxon BA, et al. Disease- and cell-specific expression of GP73 in human liver disease. Am 
J Gastroenterol 2004;99:1087-1095. 
11. Rysz J, Banach M, Cialkowska-Rysz A, Stolarek R, Barylski M, Drozdz J, Okonski P. 
Blood serum levels of IL-2, IL-6, IL-8, TNF-alpha and IL-1beta in patients on maintenance 
hemodialysis. Cell Mol Immunol 2006;3:151-154. 
12. Leman ES, Schoen RE, Magheli A, Sokoll LJ, Chan DW, Getzenberg RH. 
Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal 
cancer. Clin Cancer Res 2008;14:1349-1354. 
13. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, et 
al. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic 
lesions and hepatocellular carcinomas. Hum Pathol 2006;37:1435-1441. 
14. Kladney RD, Bulla GA, Guo L, Mason AL, Tollefson AE, Simon DJ, Koutoubi Z, et 
al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 
2000;249:53-65. 
15. Norton PA, Comunale MA, Krakover J, Rodemich L, Pirog N, D'Amelio A, Philip R, 
et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 
2008;104:136-149. 
16. Bachert C, Fimmel C, Linstedt AD. Endosomal trafficking and proprotein 
convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular 
carcinoma. Traffic 2007;8:1415-1423. 
17. Giannelli G, Antonaci S. New frontiers in biomarkers for hepatocellular 
carcinoma. Dig Liver Dis 2006;38:854-859. 
18. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant 
BC, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate 
  
HEP-08-1321.R1  20  
with liver cancer in woodchucks and humans. Proc Natl Acad Sci U S A 2005;102:779-
784. 
19. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, et al. 
Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a 
prospective study. Hepatology 1997;25:754-758. 
20. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, et al. Predictors 
of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not 
hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-
ribavirin combination therapy. J Gastroenterol Hepatol 2007;22:669-675. 
21. Fritzsche FR, Riener MO, Dietel M, Moch H, Jung K, Kristiansen G. GOLPH2 
expression in renal cell cancer. BMC Urol 2008;8:15. 
22. Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, 
Granger J, et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate 
cancer. Neoplasia 2008;10:1285-1294. 
23. Gu Y, Chen W, Zhao Y, Chen L, Peng T. Quantitative analysis of elevated serum 
Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 2008. 
 
 
 
 
 
 
 
 
 
  
HEP-08-1321.R1  21  
Figure legend 
 
Figure 1. GOLPH2 Expression in normal liver, bile duct and gall bladder 
A,B Perinuclear GOLPH2 positivity in bile duct (arrow) and in single periportal 
hepatocytes (arrowhead) while the majority of hepatocytes is negative. C Normal gall 
bladder weakly positive for GOLPH2. Mesenchymal cells weakly positive for GOLPH2 
(arrow). 
 
Figure 2. GOLHP2 expression in liver cirrhosis and hepatocellular carcinomas 
A HCV induced liver cirrhosis negative for GOLPH2. B HCV induced liver cirrhosis 
strongly positive for GOLPH2. Hepatocellular carcinoma negative (C), weak (D), 
moderate (E) and strong (F) GOLPH2 positive. 
 
Figure 3. GOLPH2 expression in bile duct carcinomas 
Bile Duct Carcinoma negative (A) for GOLPH2 expression. Weak (B) and moderate (C) 
GOLPH2 granular positivity (arrow). Strong (D) GOLPH2 expression in clusters (arrow). 
Mesenchymal cells positive for GOLPH2 (arrowheads). 
 
Figure 4A. Scheme of Sandwich ELISA 
GOLPH2 depicted with the N-terminal proprotein convertase cleavage site and antibody 
binding sites (black aa 67-81, grey aa 302-402). Polyclonal goat anti GOLPH2 (black)) 
served as capture antibody. Polyclonal rabbit anti GOLPH2 (grey) secondary bound by a 
anti rabbit peroxidase labelled antibody (white asterisk) was used for detection 
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Figure 4B. GOLPH2 sandwich ELISA. 
GOLPH2 was detected by a sandwich ELISA in 113 serum samples,12 healthy controls, 
29 patients with HCV infection, 10 cases of bile duct carcinoma (BDC) and 62 patients 
with HCC. Out of 62 HCC patients 15 had alcohol-induced liver disease (AiLD), 18 were 
HCV positive. Displayed are boxplots of the different groups. An asterisk marks 
statistically significant difference revealed by the two tailed student´s t test between: 
 Controls and HCC with HCV (p=0.038), controls and HCC with HCV 1b (p=0.014) and 
controls and BDC (p=0.0052) 
 
Figure 5. Comparative analysis of GOLPH2 and AFP serum levels in HCC. 
Dark green columns mark patients with elevated GOLPH2 but normal AFP. Light green 
columns mark cases with both GOLPH2 and AFP increased. 
1-17: GOLPH2 elevated, AFP normal range (28%) 
17-25: GOLPH2 and AFP normal range  (14%) 
26-43: GOLPH2 normal range, AFP elevated (31%) 
44-59: GOLPH2 and AFP elevated   (27%) 
For individual patient HCC etiologies see supplemental Table 3 for case details of Fig.5 
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Supplemental Figure 1. GOLPH2 expression and survival in patients with 
hepatocellular carcinoma (HCC) and bile duct carcinoma (BDC) 
 
Supplemental Figure 2. GOLPH2 expression in FNH and LCA 
A Corresponding peritumoral liver tissue of FNH negative for GOLPH2. B FNH negative 
for GOLPH2. C Corresponding peritumoral liver tissue of LCA and LCA (D) strongly 
positive for GOLPH2. 
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